Lovenox® (Enoxaparin) Prefilled Syringes for DVT, PE, and ACS

What Lovenox® Is and How It Works

Lovenox® (enoxaparin) is a low molecular weight heparin used to prevent and treat blood clots, including deep vein thrombosis (DVT) and pulmonary embolism (PE). It is also used in certain acute coronary syndromes (ACS). Lovenox Injections are given by subcutaneous injection, most often once or twice daily, depending on the indication and dose. CanadianInsulin is a prescription referral service. Prescriptions are verified with your clinic, and orders are filled by licensed Canadian pharmacies. We source authentic brand medications through licensed, vetted partner pharmacies, with a broad selection and value-focused pricing.

Enoxaparin enhances antithrombin activity against factor Xa and IIa, which reduces clot formation. Compared with unfractionated heparin, it offers more predictable anticoagulation and does not typically require routine lab monitoring. Fixed or weight-based dosing is used based on the clinical situation.

Dosage and Usage

Use and dose are set by a healthcare professional and depend on the condition, kidney function, and bleeding risk.

• Initiation: Prophylaxis after surgery is often 40 mg once daily or 30 mg every 12 hours. Treatment dosing commonly uses 1 mg/kg every 12 hours or 1.5 mg/kg once daily.
• Special cases: Renal impairment may require dose adjustment and closer observation. Pediatric and very low or high body weight patients need individualized dosing.
• Missed dose: If a dose is missed, take it as soon as remembered unless it is near the time for the next dose. Do not double doses; contact the prescriber for guidance.
• Injection route: Subcutaneous only. Do not administer intramuscularly.
• Injection sites: Abdomen at least two inches from the navel; rotate sites. Thigh is an acceptable alternative site. Avoid scars, bruised areas, or irritated skin.
• Technique: Use prefilled syringes; do not expel the air bubble unless instructed by a clinician. Pinch a fold of skin, insert the needle at 90 degrees (or 45 degrees if needed based on habitus), inject slowly, and remove needle straight out.
• After injection: Do not rub the site. Apply gentle pressure with gauze if needed.
• Device specifics: Lovenox prefilled syringes come in multiple strengths, including enoxaparin sodium 40 mg and 80 mg/0.8 mL. Follow the syringe markings for the prescribed dose.

• Storage: Store at 20–25°C (68–77°F). Excursions 15–30°C (59–86°F) are usually acceptable. Do not freeze. Protect from excessive heat and light.
• Packaging: Keep syringes in the original carton until use.
• Handling: Keep out of reach of children. Dispose of used syringes in an FDA-cleared sharps container.
• Travel: Carry medication in hand luggage with the prescription label. Use an insulated pouch if temperatures may exceed 30°C (86°F) for prolonged periods. Do not leave syringes in a hot car.

Benefits and Savings

Lovenox helps lower the risk of DVT and PE in high‑risk settings and treats existing clots. It offers predictable, weight‑based dosing without routine coagulation monitoring in most patients. Subcutaneous administration supports at‑home care and short hospital stays. It is widely used in pregnancy when an anticoagulant is indicated.

Many customers save 60–80% vs typical U.S. prices. See our promotions page for current offers, including any lovenox injection coupons if available.

Side Effects and Safety

• Common: Injection‑site pain, bruising, and redness; mild bleeding (e.g., gums, nosebleeds); anemia; nausea; elevated liver enzymes.
• Less common: Thrombocytopenia, including heparin‑induced thrombocytopenia (HIT); rash; edema.
• Local: Small subcutaneous hematomas at the injection site.

Serious risks include major bleeding, HIT, and spinal/epidural hematomas when used with neuraxial anesthesia or spinal puncture. Patients with active major bleeding, a history of HIT, or hypersensitivity to enoxaparin/heparin/porcine products should not receive it. Caution is required with concurrent antiplatelets, NSAIDs, or other anticoagulants. Clinicians monitor for signs of bleeding and thrombocytopenia and manage neuraxial procedures with strict timing protocols.

Onset Time

After subcutaneous administration, anti‑factor Xa activity rises within hours, with peak effect around 3–5 hours. Prophylaxis benefit begins with the first doses during the risk period. In treatment of DVT/PE, symptom improvement may take days, while risk reduction for extension/embolization occurs as therapeutic levels are maintained.

Compare With Alternatives

Several anticoagulants are used for similar goals, but they differ in route, monitoring, and dosing.

Xarelto® (rivaroxaban) is an oral factor Xa inhibitor with once‑daily or twice‑daily dosing depending on indication. It avoids injections and routine lab monitoring. See Xarelto for details on available strengths.

Apixaban is another oral factor Xa inhibitor with twice‑daily dosing for many indications. It is used for DVT/PE treatment and prophylaxis in medical and surgical settings. See Apixaban to compare options.

Plavix® (clopidogrel) is an antiplatelet agent used after stenting and in acute coronary syndromes to prevent arterial thrombosis. It is not a direct substitute for enoxaparin in VTE treatment, but it may be used alongside or sequentially in ACS care as directed by a cardiology team.

Choice depends on clinical scenario, renal function, bleeding risk, pregnancy status, and procedural considerations. Parenteral Lovenox remains valuable when rapid onset, bridging, or pregnancy‑compatible anticoagulation is needed.

Combination Therapy

• Bridging to warfarin: Enoxaparin is often overlapped with warfarin until the INR is therapeutic, then discontinued.
• With antiplatelets: In ACS, enoxaparin may be combined with aspirin or a P2Y12 inhibitor; bleeding risk increases and requires careful oversight.
• With DOACs: Concomitant therapeutic‑dose use with agents like rivaroxaban or apixaban is generally avoided due to bleeding risk; transitions follow structured timing.
• Procedures and neuraxial anesthesia: Timing of doses around spinal/epidural catheters is critical to reduce hematoma risk.
• Mechanical methods: Graduated compression or intermittent pneumatic compression may be added for enhanced prophylaxis in selected patients.

Patient Suitability and Cost-Saving Tips

Lovenox is considered for adults at risk for or being treated for venous thromboembolism, including post‑operative patients and those with limited mobility, active cancer, or acute medical illness. It also plays a role in ACS care and is commonly used when an anticoagulant is indicated during pregnancy.

It may not be appropriate in active major bleeding, history of HIT, severe uncontrolled hypertension, recent hemorrhagic stroke, severe renal impairment without dose adjustment and monitoring, or in the presence of spinal/epidural catheters without careful timing. Porcine protein sensitivity is another reason to avoid use.

Cost‑saving tips include considering multi‑month orders when appropriate, selecting strengths that match the prescribed dose to reduce waste, and discussing generic enoxaparin sodium options when clinically suitable. Reorder reminders can help maintain therapy continuity and avoid urgent local purchases at higher prices.

Authoritative Sources

Sanofi Lovenox (official U.S. product page)

FDA Prescribing Information for Lovenox

Health Canada Drug Product Database (Lovenox entry)

Order Lovenox from CanadianInsulin: add to cart, upload your prescription, and we ship with prompt, express, cold‑chain handling.

This page is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.